Mr. Dumoulin-White concluded that, “The Company looks forward to successfully reporting out on the first 3 patients treated in the Phase Ib clinical study for NMIBC in late May 2017. If successful, this will allow the Company to significantly de-risk its PDT technology and increase shareholder value by successfully transforming from a preclinical to a clinical organization in the field of oncology.”